Alto Ingredients And 2 Other US Penny Stocks To Watch Closely

As major U.S. stock indexes experience slight declines amid a wave of earnings reports, investors are keeping a close eye on market movements and economic indicators. In this context, penny stocks—once considered speculative investments—remain relevant for those seeking opportunities in smaller or newer companies with solid financials. These stocks can offer potential growth at lower price points, especially when backed by strong balance sheets and fundamentals.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Financial Health Rating
BAB (OTCPK:BABB)	$0.7988	$5.8M	★★★★★★
LexinFintech Holdings (NasdaqGS:LX)	$3.15	$485.02M	★★★★★★
Flexible Solutions International (NYSEAM:FSI)	$3.47	$45.02M	★★★★★★
RLX Technology (NYSE:RLX)	$1.62	$2.1B	★★★★★★
ARC Document Solutions (NYSE:ARC)	$3.42	$147.91M	★★★★★★
Imperial Petroleum (NasdaqCM:IMPP)	$3.77	$114.05M	★★★★★★
Permianville Royalty Trust (NYSE:PVL)	$1.57	$52.63M	★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U)	$4.50	$69.71M	★★★★★★
PHX Minerals (NYSE:PHX)	$3.63	$137.99M	★★★★★☆
CBAK Energy Technology (NasdaqCM:CBAT)	$1.09	$96.23M	★★★★★☆

Click here to see the full list of 752 stocks from our US Penny Stocks screener.

We'll examine a selection from our screener results.

Alto Ingredients (NasdaqCM:ALTO)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Alto Ingredients, Inc. is a company that produces, distributes, and markets specialty alcohols, renewable fuel, and essential ingredients in the United States with a market cap of $132.32 million.

Operations: The company's revenue is primarily derived from its Pekin Campus Production at $638.65 million, followed by Marketing and Distribution at $241.94 million, and Western Production contributing $187.55 million.

Market Cap: $132.32M

Alto Ingredients, Inc. is navigating the penny stock landscape with a market cap of US$132.32 million and a focus on specialty alcohols and renewable fuels. Despite being unprofitable, it maintains a strong cash runway exceeding three years, supported by positive free cash flow. The company's recent product enhancements at its Magic Valley facility aim to diversify its offerings with higher-margin products like high-protein and corn oil yields. While short-term assets cover both short- and long-term liabilities comfortably, challenges remain with profitability as evidenced by recent quarterly losses despite reducing debt significantly over five years.

• Click here to discover the nuances of Alto Ingredients with our detailed analytical financial health report.
• Examine Alto Ingredients' earnings growth report to understand how analysts expect it to perform.

Equillium (NasdaqCM:EQ)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Equillium, Inc. is a clinical-stage biotechnology company focused on developing and selling treatments for severe autoimmune and immuno-inflammatory disorders with unmet medical needs, with a market cap of $40.03 million.

Operations: Equillium generates revenue solely from its Pharmaceuticals segment, amounting to $42.62 million.

Market Cap: $40.03M

Equillium, Inc. is navigating the challenges of the penny stock market with a focus on developing treatments for severe autoimmune disorders. The company has reported sales of US$24.54 million for the first half of 2024, but remains unprofitable and faces a forecasted earnings decline over the next three years. Recent strategic alliances, such as with Vivtex Corporation to enhance EQ302's formulation, highlight its commitment to innovation in GI inflammation therapies. However, Equillium must address its Nasdaq listing compliance due to low share prices while managing volatility and ensuring sufficient cash runway to support ongoing operations.

• Click to explore a detailed breakdown of our findings in Equillium's financial health report.
• Learn about Equillium's future growth trajectory here.

Grove Collaborative Holdings (NYSE:GROV)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Grove Collaborative Holdings, Inc. is a plastic neutral consumer products retailer in the United States with a market cap of $59.77 million.

Operations: Grove Collaborative Holdings generates revenue primarily from its online retail segment, which accounted for $227.25 million.

Market Cap: $59.77M

Grove Collaborative Holdings is navigating the complexities of the penny stock market, with a market cap of US$59.77 million and significant revenue generation from its online retail segment, totaling US$227.25 million. Despite being unprofitable, it has reduced losses over five years by 33.4% annually and maintains a strong cash position exceeding its debt, ensuring a cash runway for over three years. Recent financial maneuvers include a shelf registration for US$9.86 million and private placements raising US$15 million, which may provide flexibility amid revised lower earnings guidance for fiscal year 2024 due to declining sales figures.

• Take a closer look at Grove Collaborative Holdings' potential here in our financial health report.
• Assess Grove Collaborative Holdings' future earnings estimates with our detailed growth reports.

Where To Now?

• Investigate our full lineup of 752 US Penny Stocks right here.
• Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.
• Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.

Want To Explore Some Alternatives?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com